---
figid: PMC8363824__gr1
figtitle: 'Novel molecular targeted therapies for patients with neurofibromatosis
  type 1 with inoperable plexiform neurofibromas: a comprehensive review'
organisms:
- NA
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
pmcid: PMC8363824
filename: gr1.jpg
figlink: /pmc/articles/PMC8363824/figure/fig1/
number: F1
caption: Intracellular tumorigenic signaling pathway of neurofibromin and mechanism
  of action of MEK inhibitors. Neurofibromin promotes the conversion of active GTP-bound
  RAS to the inactive GDP-bound conformation (left). Loss of neurofibromin increases
  RAS activity and consequently the signaling cascade of the MEK/ERK pathway. MEK
  inhibitors (selumetinib, mirdametinib, trametinib, and binimetinib) inhibit this
  protein and block the MAPK signaling cascade (right). ERK, extracellular signal-regulated
  kinase; GDP, guanidine diphosphate; GRB2, growth factor receptor-bound protein 2;
  GTP, guanidine triphosphate; MAPK, mitogen-activated protein kinase; MEK, MAPK/extracellular-signal-regulated
  kinase; NF1, neurofibromin; Raf, serine/threonine-protein kinase; SOS, son of sevenless.
papertitle: 'Novel molecular targeted therapies for patients with neurofibromatosis
  type 1 with inoperable plexiform neurofibromas: a comprehensive review.'
reftext: I. Solares, et al. ESMO Open. 2021 Aug;6(4):100223.
year: '2021'
doi: 10.1016/j.esmoop.2021.100223
journal_title: ESMO Open
journal_nlm_ta: ESMO Open
publisher_name: Elsevier
keywords: neurofibromatosis type 1 | plexiform neurofibromas | neoplasms | molecular
  targeted therapy
automl_pathway: 0.95915
figid_alias: PMC8363824__F1
figtype: Figure
redirect_from: /figures/PMC8363824__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC8363824__gr1.html
  '@type': Dataset
  description: Intracellular tumorigenic signaling pathway of neurofibromin and mechanism
    of action of MEK inhibitors. Neurofibromin promotes the conversion of active GTP-bound
    RAS to the inactive GDP-bound conformation (left). Loss of neurofibromin increases
    RAS activity and consequently the signaling cascade of the MEK/ERK pathway. MEK
    inhibitors (selumetinib, mirdametinib, trametinib, and binimetinib) inhibit this
    protein and block the MAPK signaling cascade (right). ERK, extracellular signal-regulated
    kinase; GDP, guanidine diphosphate; GRB2, growth factor receptor-bound protein
    2; GTP, guanidine triphosphate; MAPK, mitogen-activated protein kinase; MEK, MAPK/extracellular-signal-regulated
    kinase; NF1, neurofibromin; Raf, serine/threonine-protein kinase; SOS, son of
    sevenless.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - ras
  - Ras64B
  - Ras85D
  - Nf1
  - Raf
  - Dsor1
  - Mtk
  - Erk7
  - rl
  - drk
  - Sos
  - CkIIbeta
  - Andorra
  - Anp
  - Acam
  - KRAS
  - HRAS
  - NRAS
  - NF1
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - EPHB2
  - MAPK1
  - MAPK3
  - GRB2
  - XYLT2
  - SOS1
  - SOS2
  - MTG1
  - UQCC2
---
